CytoMed Therapeutics Limited (NASDAQ:GDTC) Short Interest Down 13.5% in February

CytoMed Therapeutics Limited (NASDAQ:GDTC) saw a significant decrease in short interest in the month of February. As of February 28th, there was short interest totalling 127,800 shares, a decrease of 13.5% from the February 13th total of 147,800 shares. Based on an average trading volume of 199,100 shares, the short-interest ratio is presently 0.6 days. Currently, 3.2% of the company’s shares are short sold.

CytoMed Therapeutics Price Performance

GDTC stock traded up $0.06 during midday trading on Wednesday, hitting $2.69. 241 shares of the company’s stock were exchanged, compared to its average volume of 75,326. CytoMed Therapeutics has a 1-year low of $1.20 and a 1-year high of $4.05. The business has a 50-day simple moving average of $2.61 and a two-hundred day simple moving average of $2.38.

CytoMed Therapeutics Company Profile

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.